• Home
  • About
  • Sales Center
  • Product
  • Gallery
  • Contact
  • Webmail

Itrafun

Generic Name: Itraconazole

Therapeutic Class: ANTIFUNGAL


Dosage Form: Capsule


View Prescribing


  • Presentation
  • Description
  • Indications
  • Dosage & Administration
  • Side Effect
  • Precautions
  • Contraindications
  • Drug Interaction
  • Storage

Presentation

Itrafun

Description

Itrafun is an orally active triazole antifungal drug that has demonstrated a  broad  spectrum  of  activity  and  favorable  pharmacokinetic  profile. Itraconazole inhibits Cytochrome P-450 dependent enzymes resulting in impairment of the biosynthesis of ergosterol, a major component of the cell membrane of yeast and fungal cells. Being integral to the proper functioning of the cell membrane, inhibition of the synthesis of ergosterol leads to a cascade of abnormalities in permeability, membrane bound enzyme activity, and  co-ordination  of  chitin  synthesis  leading  to  inhibition  of  growth, abnormal cell wall formation and accumulation of intracellular lipids and membranous vesicles.

Itrafun

Indication

Itrafun (Itraconazole) is used for the treatment of oropharyngeal candidiasis, vulvovaginal candidiasis, pityriasis versicolor, tinea pedis, tinea cruris, tinea corporis, tinea manuum, onychomycosis, histoplasmosis. It is indicated in the treatment of systemic candidiasis, aspergillosis, and cryptococcosis (including cryptococcal meningitis). It is also used for maintenance therapy in AIDS patients to prevent relapse of underlying fungal infections and in the prevention of fungal infection during prolonged neutropenia.

Itrafun

Dosage & Administration

Route of administration: Oral
Oropharyngeal  candidiasis: 100  mg  daily (200  mg  daily  in  AIDS  or neutropenia) for 15 days.
Vulvovaginal candidiasis: 200 mg twice daily for 1 day. Pityriasis versicolor: 200 mg daily for 7 days.
Tinea corporis and tinea cruris: either 100 mg daily for 15 days or 200 mg daily for 7 days.
Tinea pedis and tinea manuum: either 100 mg daily for 30 days or 200 mg twice daily for 7 days.
Onychomycosis: either 200 mg daily for 3 months or course (pulse) of 200 mg twice daily for 7 days, subsequent courses repeated after 21 days interval. Fingernails two courses, toenails three courses.
Systemic infections (aspergillosis, candidiasis and cryptococcosis including cryptococcal  meningitis)  where  other  antifungal  drugs  inappropriate  or ineffective: 200 mg once daily, increased in invasive or disseminated disease and in cryptococcal meningitis to 200 mg twice daily.
Histoplasmosis: 200 mg 1-2 times daily. Maintenance in AIDS patients to prevent  relapse  of  underlying  fungal  infection  and  prophylaxis  in neutropenia when standard therapy is inappropriate: 200 mg once daily, increased to 200 mg twice daily if low plasma Itraconazole concentration is detected.

Child dose: the recommended dose is 3 to 5 mg/kg/day.

Itrafun

Side Effect

Common side effects: Nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, menstrual disorders, allergic reactions (including pruritus, rash, urticaria and angioedema), hepatitis and cholestatic jaundice, peripheral neuropathy and Stevens-Johnson syndrome reported.
Rare side effects: On prolonged use hypokalaemia, oedema and hair loss reported.

Itrafun

Precautions

Absorption is impaired when gastric acidity is reduced. In patients receiving acid neutralizing medicines (e.g. aluminium hydroxide), these should be administered at least 2 hours after the intake of Itrafun. The drug should be administered after a full meal. Rarely, cases of hepatitis and jaundice have been reported mainly in patients treated for longer than one month. It is therefore, advised to monitor liver function in patients receiving continuous treatment of more than one month.

Capsule should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or history of CHF.

Itrafun

Contraindications

Itrafun is contraindicated in patients with known hypersensitivity to the drug or any ingredient in the formulation. Patients who have severe hepatic disease are not advised to take Itrafun. It is not advisable to use the drug in patients taking rifampin, which appears to initially inhibit and then enhance the metabolism of Itraconazole.

Itrafun

Drug Interaction

With medicine: The  drugs  like  terfenadine,  astemizole,  cisapride,  HMG-CoA  reductase inhibitors such as simvastatin, oral midazolam or triazolam should not be given concurrently with Itrafun. Significant interactions also observed during co-administration of rifampin, phenytoin, phenobarbital, digoxin, and calcium channel blockers.

With Food & Others: Relevant data is not available

Itrafun

Storage

Store in a cool and dry place below 30 degree  C, away from light.

Itrafun